Evidence map›Paper›PMID 22361336›Full record

ArticleThe Lancet. Oncology2012

Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies.

Celeste Leigh Pearce, Claire Templeman, Mary Anne Rossing, Alice Lee, Aimee M Near, Penelope M Webb, Christina M Nagle, Jennifer A Doherty, Kara L Cushing-Haugen, Kristine G Wicklund and 36 more

Open access · hybridAbstract read
In one paragraph

Article in The Lancet. Oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 440 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
440citing papers in PubMed, 9 pooled it
73.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

440 citing papers in PubMed, 9 syntheses or guidelines pooled it, 916 citations in OpenAlex.

  1. Morphological and molecular characterization of epithelial ovarian cancer: SEOM-SEAP consensus guidelines for biomarker integration in clinical practice.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. A Systematic Review of Atypical Endometriosis-Associated Biomarkers.International journal of molecular sciences · 2022
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

380 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

46 authors at 20 institutions in 6 countries.

Celeste Leigh PearceDepartment of Preventive Medicine, University of Southern California, Los Angeles, CA, USA. cpearce@usc.edu
Claire Templeman
Mary Anne Rossing
Alice Lee
Aimee M Near
Penelope M Webb
Christina M Nagle
Jennifer A Doherty
Kara L Cushing-Haugen
Kristine G Wicklund
Jenny Chang-Claude
Rebecca Hein
Galina Lurie
Lynne R Wilkens
Michael E Carney
Marc T Goodman
Kirsten Moysich
Susanne K Kjaer
Estrid Hogdall
Allan Jensen
Ellen L Goode
Brooke L Fridley
Melissa C Larson
Joellen M Schildkraut
Rachel T Palmieri
Daniel W Cramer
Kathryn L Terry
Allison F Vitonis
Linda J Titus
Argyrios Ziogas
Wendy Brewster
Hoda Anton-Culver
Alexandra Gentry-Maharaj
Susan J Ramus
A Rebecca Anderson
Doerthe Brueggmann
Peter A Fasching
Simon A Gayther
David G Huntsman
Usha Menon
Roberta B Ness
Malcolm C Pike
Harvey Risch
Anna H Wu
Andrew Berchuck
Ovarian Cancer Association Consortium
University of Southern California · USFred Hutch Cancer Center · USBrigham and Women's Hospital · USMayo Clinic · USDanish Cancer Society · DKQIMR Berghofer Medical Research Institute · AUUniversity College London · GBUniversity of California, Irvine · USUniversity of Hawaii System · USBC Cancer Agency · CACancer Research Center · USDartmouth College · USDuke Medical Center · USDuke University Hospital · USGeorgetown University Medical Center · USGerman Cancer Research Center · DEHeidelberg University · DEMemorial Sloan Kettering Cancer Center · USRigshospitalet · DKRoswell Park Comprehensive Cancer Center · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Saul Priceman · 1985 to 2026
$181.4M
University of Hawaii Cancer Center CCSGP30CA071789 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI Xin Chen · 1996 to 2026
$56.2M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI SCOTT H KAUFMANN · 2009 to 2026
$37.0M
USC CANCER EPIDEMIOLOGY &BIOSTATISTICS UNITP01CA017054 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HAIMAN, CHRISTOPHER ALAN · 1985 to 2009
$18.2M
Novel Serum, Plasma, and Urine Biomarkers of Ovarian CanP50CA105009 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI CRAMER, DANIEL WILLIAM · 2004 to 2010
$13.3M
The Molecular Epidemiology Of Ovarian CancerR01CA076016 · NCI · DUKE UNIVERSITY · PI SCHILDKRAUT, JOELLEN M. · 1998 to 2010
$6.2M
OVARIAN CANCER RISK AND HYPERGONADOTROPIC HYPOGONADISMR01CA054419 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI CRAMER, DANIEL WILLIAM · 1992 to 2007
$5.9M
COLLABORATIVE STUDY OF OVARIAN CANCER IN TWO RISK GROUPSR01CA058598 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI GOODMAN, MARC T · 1993 to 2012
$4.6M
Epidemiology of Ovarian Cancer:New HypothesesR01CA087538 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ROSSING, MARY ANNE · 2002 to 2006
$3.5M
Steroid Hormone Genes and Ovarian Cancer RiskR01CA112523 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ROSSING, MARY ANNE · 2006 to 2010
$3.3M
HEREDITARY BREAST CANCER--GENETIC AND MOLECULAR STUDIESR01CA058860 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI ANTON-CULVER, HODA A · 1994 to 2008
$3.1M
Regulatory T Cell Function in Ovarian CancerR01CA126841 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOYSICH, KIRSTEN B. · 2009 to 2013
$3.0M
NCI NIH HHS 5R01 CA074850NCI NIH HHS CA14089NCI NIH HHS CA17054NCI NIH HHS CA58860NCI NIH HHS CA61132NCI NIH HHS CA92044NCI NIH HHS K07 CA092044NCI NIH HHS N01 CN67001NCI NIH HHS N01 PC035137NCI NIH HHS N01 PC067010NCI NIH HHS N01 PC35137NCI NIH HHS N01 PC67010NCI NIH HHS P01 CA017054NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA071789NCI NIH HHS P50 CA105009NCI NIH HHS P50 CA136393NCI NIH HHS R01 CA054419NCI NIH HHS R01 CA058598NCI NIH HHS R01 CA058860NCI NIH HHS R01 CA074850NCI NIH HHS R01 CA076016NCI NIH HHS R01 CA087538NCI NIH HHS R01 CA095023NCI NIH HHS R01 CA112523NCI NIH HHS R01 CA122443NCI NIH HHS R01 CA126841NCI NIH HHS R01 CA136891NCI NIH HHS R01 CA54419NCI NIH HHS R01 CA58598NCI NIH HHS R01 CA61107NCI NIH HHS R01 CA76016NCI NIH HHS R01 CA87538NCI NIH HHS R01 CA95023NCI NIH HHS R03 CA113148NCI NIH HHS U01 CA058860NIAID NIH HHS R01 AI048909PHS HHS PSA 042205
6 · The paper itself

Abstract

backgroundEndometriosis is a risk factor for epithelial ovarian cancer; however, whether this risk extends to all invasive histological subtypes or borderline tumours is not clear. We undertook an international collaborative study to assess the association between endometriosis and histological subtypes of ovarian cancer.

methodsData from 13 ovarian cancer case-control studies, which were part of the Ovarian Cancer Association Consortium, were pooled and logistic regression analyses were undertaken to assess the association between self-reported endometriosis and risk of ovarian cancer. Analyses of invasive cases were done with respect to histological subtypes, grade, and stage, and analyses of borderline tumours by histological subtype. Age, ethnic origin, study site, parity, and duration of oral contraceptive use were included in all analytical models.

findings13 226 controls and 7911 women with invasive ovarian cancer were included in this analysis. 818 and 738, respectively, reported a history of endometriosis. 1907 women with borderline ovarian cancer were also included in the analysis, and 168 of these reported a history of endometriosis. Self-reported endometriosis was associated with a significantly increased risk of clear-cell (136 [20·2%] of 674 cases vs 818 [6·2%] of 13 226 controls, odds ratio 3·05, 95% CI 2·43-3·84, p<0·0001), low-grade serous (31 [9·2%] of 336 cases, 2·11, 1·39-3·20, p<0·0001), and endometrioid invasive ovarian cancers (169 [13·9%] of 1220 cases, 2·04, 1·67-2·48, p<0·0001). No association was noted between endometriosis and risk of mucinous (31 [6·0%] of 516 cases, 1·02, 0·69-1·50, p=0·93) or high-grade serous invasive ovarian cancer (261 [7·1%] of 3659 cases, 1·13, 0·97-1·32, p=0·13), or borderline tumours of either subtype (serous 103 [9·0%] of 1140 cases, 1·20, 0·95-1·52, p=0·12, and mucinous 65 [8·5%] of 767 cases, 1·12, 0·84-1·48, p=0·45).

interpretationClinicians should be aware of the increased risk of specific subtypes of ovarian cancer in women with endometriosis. Future efforts should focus on understanding the mechanisms that might lead to malignant transformation of endometriosis so as to help identify subsets of women at increased risk of ovarian cancer.

fundingOvarian Cancer Research Fund, National Institutes of Health, California Cancer Research Program, California Department of Health Services, Lon V Smith Foundation, European Community's Seventh Framework Programme, German Federal Ministry of Education and Research of Germany, Programme of Clinical Biomedical Research, German Cancer Research Centre, Eve Appeal, Oak Foundation, UK National Institute of Health Research, National Health and Medical Research Council of Australia, US Army Medical Research and Materiel Command, Cancer Council Tasmania, Cancer Foundation of Western Australia, Mermaid 1, Danish Cancer Society, and Roswell Park Alliance Foundation.

Indexed as

AgedAged, 80 and overCase-Control StudiesEndometriosisEthnicityFemaleHumansMiddle AgedNeoplasm InvasivenessNeoplasm StagingOvarian NeoplasmsRisk Factors

Identifiers

PMID22361336
PMCPMC3664011
OpenAlexW2125681453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.